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Abstract
Background: Systemic lupus erythematosus (SLE) is a multifactorial disorder characterized by the
presence of autoantibodies. We and others have implicated free radical mediated peroxidative
damage in the pathogenesis of SLE. Since harmful free radical products are formed during this
oxidative process, including 4-hydroxy 2-nonenol (4-HNE) and malondialdehyde (MDA), we
hypothesized that specific HNE-protein adducts would be present in SLE red blood cell (RBC)
membranes. Catalase is located on chromosome 11p13 where linkage analysis has revealed a
marker in the same region of the genome among families with thrombocytopenia, a clinical
manifestation associated with severe lupus in SLE affected pedigrees. Moreover, SLE afflicts African-
Americans three times more frequently than their European-American counterparts. Hence we
investigated the effects of a genetic polymorphism of catalase on risk and severity of SLE in 48
pedigrees with African American ancestry.
Methods: Tryptic digestion followed by matrix assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOFMS) analysis was used to identify the protein modified by HNE,
following Coomassie staining to visualize the bands on the acrylamide gels. Genotyping analysis for
the C → T, -262 bp polymorphism in the promoter region of catalase was performed by PCR-RFLP
and direct PCR-sequencing. We used a "pedigree disequilibrium test" for the family based
association analysis, implemented in the PDT program to analyze the genotyping results.
Results: We found two proteins to be HNE-modified, migrating around 80 and 50 kD respectively.
Tryptic digestion followed by matrix assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOFMS) analysis of the Coomassie stained 80 kD band revealed that the
target of HNE modification was catalase, a protein shown to associate with RBC membrane
proteins. All the test statistics carried out on the genotyping analysis for the C → T, -262 bp
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polymorphism in the promoter region of catalase were non-significant (p > 0.05) in our data, which
suggested that this SNP is not associated with SLE.
Conclusion: Our results indicate that catalase is one of the proteins modified due to oxidative
stress. However, catalase may not be a susceptibility gene for SLE. Nonetheless, catalase is
oxidatively modified among SLE patients. This suggests a possible role between oxidative
modification of catalase and its affects on enzymatic activity in SLE. An oxidatively modified catalase
could be one of the reasons for lower enzymatic activity among SLE subjects, which in turn could
favor the accumulation of deleterious hydrogen peroxide. Furthermore, HNE-products are
potential neoantigens and could be involved in the pathogenesis of SLE. Decrease in catalase activity
could affect the oxidant-antioxidant balance. Chronic disturbance of this balance in patients with
SLE may work favorably for the premature onset of atherogenesis with severe vascular effect.
Background
SLE is a complex, multisystem disorder with an unknown
etiology and is distinguished by antibodies to self-pro-
teins [1]. It virtually involves any organ system with a
wide range of disease severity. 50–100% of SLE patients
complained of fatigue, weight loss or fever in the absence
of infection. The skin is affected in about three-fourths of
patients, in the form of butterfly rash, photosensitivity
rash, mucous membrane lesion, alopecia, Raynaud's phe-
nomenon, purpura, urticaria or vasculitis. Two-thirds
have musculoskeletal problems (arthritis, myositis or
arthralgia). Renal problems are found in 16–38% of
patients (proteinuria, haematuria, cellular casts or
nephritic syndrome) [2]. Thirty-six per cent suffer from
haematological problems (thrombocytopenia, anaemia
or leucopenia) [3,4]. Reticuloendothelial anomaly is seen
in 7–23% of patients (splenomegaly, lymphadenopathy
or hepatomegaly). Neuropsychiatric problems are seen in
12–21% of patients (seizures, psychosis, transverse myeli-
tis, brain syndrome, cranial neuropathies, and peripheral
neuropathies); 18% suffer from gastrointestinal problems
(vomiting, nausea or abdominal pain). Pulmonary prob-
lems are seen in 2–12% of the affected (pulmonary hyper-
tension, pleurisy or pulmonary parenchymal disease [5].
Cardiac abnormalities are seen in 15% of patients (endo-
carditis, pericarditis or myocarditis).
Our earlier data showed oxidative damage occurring in
SLE with significantly elevated conjugated diene and
malondialdehyde formation [6]. Since a variety of harm-
ful fragmentation products are formed during the oxida-
tive process, including 4-HNE, which react with proteins
to form potentially dangerous protein adducts [7], we
hypothesized that specific HNE-protein adducts would be
present in SLE. We investigated RBC membranes from 8
SLE and 11 normal subjects for HNE-modified proteins.
We found two proteins to be HNE-modified, migrating
around 80 and 50 kD, respectively. Tryptic digestion fol-
lowed by MALDI-TOFMS analysis of the Coomassie
stained 80 kD band revealed that the target of HNE mod-
ification was catalase, a protein shown to associate with
RBC membrane proteins. RBC lysate catalase was not
found to be modified, showing specificity of modifica-
tion. We studied only the 80 kD band since this was found
to be the most prominently affected in the SLE patients.
Catalase is an important endogenous antioxidant enzyme
that detoxifies hydrogen peroxide to oxygen and water,
thus limiting the deleterious effects of highly reactive oxy-
gen species (ROS) [8]. Hence, catalase has been consid-
ered an important regulator of oxidative stress wherein
chronic exposure to ROS may contribute to the develop-
ment of SLE [9]. Catalase is located on chromosome
11p13 [10] where genetic linkage has been found among
African-American SLE families with thrombocytopenia, a
clinical manifestation associated with severe lupus in SLE
affected pedigrees [11]. Moreover, African-Americans are
three times more likely to be affected by SLE than Euro-
pean Americans, manifest SLE at an earlier age, and have
a clinically more severe phenotype than other American
racial groups [12]; however, there have been no genetic
studies that have directly focused on the contribution of
the catalase gene to SLE in African Americans. Because of
its location within the 11p13 genetic linkage for SLE, we
investigated a genetic polymorphism of the catalase gene
[C(-262)T (rs1001179)], on the risk and severity of SLE in
48 pedigrees with African-American ethnic background
and found no genetic associations.
Methods
Materials
Anti-4-HNE keyhole limpet hemocyanin was obtained
from Biotrend Chemikalien, Cologne, Germany. Anti-rab-
bit IgG alkaline phosphatase conjugate was from Jackson
Laboratories, Bar Harbor, ME. ECL plus chemilumines-
cence kit was from Amersham Biosciences, Piscataway, NJ.
Bicinchoninic acid (BCA) protein assay kit was from
Pierce Chemical Company, Rockford, IL. Pre-cast sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS
PAGE) gels (4–20% gradient gel) were from ISC Bioex-
press, Kaysville, UT. HotStart DNA polymerase kit was
purchased from Qiagen. All primers were synthesized byBMC Medical Genetics 2008, 9:62 http://www.biomedcentral.com/1471-2350/9/62
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Molecular Biology Resource facility at OMRF. All other
reagents used were of reagent grade.
Human sera and study participants
Blood was drawn under a protocol approved by the Insti-
tutional Review Board. All patients satisfied the 1982
American Rheumatism Association revised criteria for the
classification of SLE [13]. SLE patients and their family
members were enrolled in the lupus genetics studies pre-
viously described [14]. Enrollment of a family required at
least 2 members who fulfill the 1982 revised or modified
criteria for SLE, as previously reported and whose relation-
ship was informative for linkage with an SLE phenotype.
All patient material was gathered under protocols
approved by the Oklahoma Medical Research Foundation
and University of Oklahoma Health Sciences Center Insti-
tutional Review Boards and after informed consent was
obtained from participants. Clinical manifestations were
defined as either present or absent based on the defini-
tions in the SLE classification criteria. Sera was serologi-
cally evaluated for ANA, anti-double-stranded (ds) DNA,
anti-Sm, antiphospholipid immunoglobulin G (IgG) and
IgM antibodies using specimens obtained for this project
by following standard procedures. Anti-Ro, anti-La, anti-
P, and anti-nRNP (nuclear ribonucleoprotein) were also
evaluated by using Ouchterlony immunodiffusion in
each affected subject. Evidence for biologic false-positive
test for syphilis and the lupus anticoagulant was extracted
from the medical record. These clinical evaluations are
performed routinely as part of patient and sample recruit-
ment (11).
Purification of red blood cell (RBC) membranes and 
preparation of membrane ghost
Red blood cells were purified from the peripheral blood of
eight SLE patients and eleven age and sex matched con-
trols. Membrane ghosts were prepared by hypotonic lysis
[15].
Detection of HNE-modified proteins in RBC membranes
The RBC membrane proteins were quantified using the
Pierce's BCA Protein Assay kit using bovine serum albu-
min (BSA) as the standard. RBC samples were analyzed on
pre-cast SDS PAGE [16] gels (4–20% gradient gel) (ISC
Bioexpress, Kaysville, UT). Equal amounts of protein were
loaded in all lanes. Gels were electrophoretically [17]
transferred onto nitrocellulose membranes. Following
blocking, the membranes were probed with rabbit anti-
HNE antibodies (Biotrend Chemikalien, Cologne, Ger-
many). The membranes were washed thrice with Tris-
buffered saline, pH 7.4 (five minutes each) and then incu-
bated with anti-rabbit IgG horseradish peroxidase conju-
gate for 1 hour. The wash was repeated and the HNE-
modified proteins were visualized using ECL plus Western
blotting system chemiluminescence kit (Amersham Bio-
sciences, Piscataway, NJ).
Three RBC samples were chosen and a gel was run with
two identical halves. After electrophoresis, the gel was cut
in half. One half was immunoblotted; the other was
stained with Coomassie blue and dried. The Coomassie
stained band which migrated at 80 kD was excised from
the gel after comparison with an identical anti-HNE-
stained immunoblot and subjected to in-gel tryptic diges-
tion. The tryptic fragments were analyzed using MALDI-
TOFMS and a database search was used to identify the
HNE-modified proteins [18].
Catalase genotyping
DNA was isolated from blood samples collected from 223
individuals (100 affected and 113 matching controls (also
see table 1). Genotyping was conducted by restriction-
fragment length polymorphism (RFLP)-PCR, without
knowledge of subject status. Genotyping analysis for the C
→ T, -262 bp polymorphism in the promoter region of
catalase was performed by PCR-RFLP and direct PCR-
sequencing (Figure 1). Approximately 10 ng of DNA was
amplified by thermal cycling using the HotStart DNA
polymerase kit with PCR buffer containing 1.5 mM
MgCl2, 0.2 mM of each dNTP, 0.5 U Taq, and 8 pmol of
each primer. PCR conditions included an initial denatur-
ation at 95°C for 15 min followed by 35 cycles of 94°C
for 30 s, 60°C for 45 s, and 72°C for 30 s, with a final
extension at 72°C for 10 min. Following restriction
Table 1: Catalase SNP (rs 1000179) in cases with SLE and normal 
controls and pedigree disequilibrium test
SLE (cases) Controls
Males Females Males Females
Participants 9 102 28 84
C/C genotype 7 90 28 74
C/T genotype 2 12 0 10
S1 (avg) S2(sum) S3(genotype)
TD0 (both) 0.776 0.8575 0.8575
TD1 (only sib pairs) 0.9263 1 1
TD2 (only triads) 0.3173 0.3173 0.3173
We have used 48 multigenerational, multiplex families for our family-
based association analysis using the PDT program [19]. The test 
retains a key property of the "transmission disequilibrium test 
(TDT)", in that it is valid even when there is population substructure 
or stratification. The PDT program performs both allele-specific and 
genotype-specific LD analysis of individual markers. T-test was used 
to assess the significance of for mean differences in general 
characteristics between SLE and normal subjects. We did not find a 
single individual in our pedigrees that presented with a T/T genotype, 
though the reported T/T genotype in African American population is 
3.2%.BMC Medical Genetics 2008, 9:62 http://www.biomedcentral.com/1471-2350/9/62
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enzyme digestion (2 U), products were stained with ethid-
ium bromide, resolved by 2% agarose gel electrophoresis
and visualized using a FluorChem UV imaging system or
in most cases sequenced directly.
The CAT -262 C → T promoter polymorphism was geno-
typed using the following primers: F: 5'-attccgtctgcaaaact-
ggc-3' and R: 5'-gagcctcgccccgccggcccg-3'. The T allele
eliminates a SmaI restriction site. The primers amplify a
126-bp fragment that is cut into 99 and 27 bp fragments
in the wild-type C allele, while if the T allele is present
SmaI does not cut resulting in the full length PCR product
(Figure 2). Using a unique three base SNP assay developed
in house, we further studied 4 additional SNP's (RS
1049982, RS 11546300, RS 3180560 and RS 769217) that
span the catalase gene, including the 5' and 3' UTR
regions.
Statistical analysis
We have used 48 multigenerational, multiplex families for
our family-based association analysis. Our data consists of
larger pedigrees with multiple nuclear families and/or dis-
cordant sib-ships. Therefore, it was desirable to have a
valid statistical test of association (linkage disequilib-
rium) that can use all potentially informative data, even
from the extended pedigrees. To do that, we have used a
"pedigree disequilibrium test" in our family based associ-
ation analysis, implemented in the PDT program [19].
The test retains a key property of the "transmission dise-
quilibrium test (TDT)", in that it is valid even when there
is population substructure or stratification. The PDT pro-
gram performs both allele-specific and genotype-specific
linkage disequilibrium analysis of individual markers. T-
test was used to assess the significance of mean differences
in general characteristics between SLE and normal sub-
jects.
Results and Discussion
Our interest to see whether oxidative damage occurred in
RBC membranes of SLE patients stemmed from our obser-
vation of increased oxidative damage in the sera of SLE
patients compared to normals. Upon loading equal
amounts of proteins in all lanes during electrophoresis,
the anti-HNE antibodies recognized two proteins, migrat-
ing approximately at 80 and 50 kD. These proteins were
not detected in the normal membrane samples above
background (Figure 3). This showed that oxidative dam-
age had occurred in the RBC membranes of SLE patients.
The targets of HNE-modification were limited and similar
between patients. In order to identify one of the modified
proteins, the 80 kD band was excised out of SDS PAGE
gels and subjected to tryptic digestion followed by
MALDI-TOF MS. Nine out of ten times the results of mass
spectrometric analysis (Figure 4) identified the target of
modification as catalase. Results were inconclusive one
time consequent to insufficient protein. It does appear
that catalase may be susceptible to HNE-modification
even in normal patients as there is some evidence of it (see
lane 9), however, such modification is more intense and
more common in the SLE patients.
RBC membranes are rich in polyunsaturated fatty acids
and hence are potential targets for oxidative modification.
Lipid peroxidation occurs as part of the oxygen toxicity
process when increased oxidative stress disrupts the
prooxidant/antioxidant balance. During this process free
radicals mediate oxidative damage of polyunsaturated
fatty acids. We were interested to identify proteins that
were modified by HNE, the most studied form of the 4-
hydroxy-2-alkenal group of α, β-unsaturated aldehydes.
HNE has two very electrophilic sites, the alkene bond and
the aldehyde group. The alkene bond reacts with three
nucleophilic amino acids, cysteine, lysine, and histidine.
Representative partial chromatograms: Sequencing of the  PCR product were obtained using the following two primers;  F: 5'-attccgtctgcaaaactggc-3' and R: 5'-gagcctcgccccgccggcccg- 3' Figure 1
Representative partial chromatograms: Sequencing 
of the PCR product were obtained using the follow-
ing two primers; F: 5'-attccgtctgcaaaactggc-3' and R: 
5'-gagcctcgccccgccggcccg-3'. The top panel depicts the 
sequence from a normal homozygous allele and the bottom 
panel depicts the sequence form an affected individual. The 
arrows indicate the position of the base that is variable 
between the heterozygous sample (bottom panel), where 
both bases, T and C, are present on the two alleles and the 
wild type sample (top panel).BMC Medical Genetics 2008, 9:62 http://www.biomedcentral.com/1471-2350/9/62
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The product of this reaction is thought to be the cyclic
hemiacetal form that equilibriates with the open chain
aldehyde form. The free aldehyde in the open chain ena-
bles it to react with a second amino acid and thus act as
heterobifunctional crosslinking agents.
Catalase, a tetrameric antioxidant enzyme with a molecu-
lar weight of 59800, catalyses the hydrolysis of the delete-
rious hydrogen peroxide, formed by the action of
superoxide dismutase (SOD) to water. In our results, we
find a discrepancy in the migration of catalase, which
migrates around 80 kD. This anomaly in electrophoretic
migration is possibly a direct result of modification with
HNE, with the additional HNE molecules resulting in a
higher molecular weight. It may be also possible that the
additional HNE molecules hinder migration. Studies have
shown catalase to be cytosolic. However, previous data
have shown catalase interacting with cell membrane pro-
teins and also shown the enzyme to be found in mem-
brane isolates [20].
The finding that catalase is a target of HNE-modification
in SLE raises interesting questions. Catalase, part of the
defense system against free radical damage, is itself a tar-
get. Though catalase has been affected, there is no wide-
spread free radical damage, as might be expected. This
may be due to the fact that cytosolic catalase appeared to
be unaffected or due to the increased scavenging of hydro-
gen peroxide by glutathione peroxidase. However, several
reports show that glutathione peroxidase activity is signif-
Restriction Fragment Length Polymorphism Analysis Figure 2
Restriction Fragment Length Polymorphism Analysis: The C/T polymorphism alters a Sma-I site in the SNP 
(rs1001179), therefore an antisense primer 5'-gagcctcgccccgccggcccg-3' that incorporates a mutation in order to abolish an 
exisiting Sma-I site was used together with sense primer 5'-attccgtctgcaaaactggc-3' which amplifies a 126 bp fragment. Hot Start 
PCR reactions were performed using 10 ng genomic DNA, without knowledge of sample status, using the following conditions; 
initial denaturation at 95°C for 15 min followed by 35 cycles of 94°C for 30 s, 60°C for 45 s, and 72°C for 30 s, with a final 
extension at 72°C for 10 min. The entire reaction was then digested with 2 U of Sma-I and analysed on 2% agarose gels after 
staining with ethidium bromide and visualization on a FluorChem UV imaging system. The T allele eliminates a SmaI restriction 
site. 99 bp and 27 bp fragments are visualized in the wild-type C allele (see lanes 6, 7, 8, 10, 11, 12, 13, and 14) while the full 
length PCR product are seen in lanes 2, 3, 4, 5 and 9.
Anti-4 hydroxy-2-nonenal immunoblot of RBC membrane of  SLE and control samples: RBC membrane ghosts were pre- pared as mentioned earlier Figure 3
Anti-4 hydroxy-2-nonenal immunoblot of RBC mem-
brane of SLE and control samples: RBC membrane 
ghosts were prepared as mentioned earlier. Equal 
amounts of protein samples were electrophoresed and trans-
ferred to nitrocellulose membrane and immunoblotted with 
anti-HNE antibodies. Anti-rabbit horseradish peroxidase 
conjugate was added and the blots were developed using 
chemiluminecence. Lanes 1–4 corresponds to RBC mem-
branes obtained from SLE samples while lanes 5–9 corre-
spond to normal controls. The samples were analyzed at 
random on the gel and later cut out and aligned after identifi-
cation as either SLE or normals. 'M' stands for molecular 
weight standard.BMC Medical Genetics 2008, 9:62 http://www.biomedcentral.com/1471-2350/9/62
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icantly lowered in SLE [21,22]. These studies also showed
decreased levels of reduced glutathione and elevated lev-
els of oxidized glutathione as well as decreased catalase
and SOD activities. The decrease in catalase activity could
be due to modified catalase bound to RBC membrane,
which together with decreased glutathione peroxidase
activity could favor the accumulation of hydrogen perox-
ide. This in the presence of ferrous ions leads to the more
deleterious hydroxyl radicals through Fenton's reaction.
Preliminary results show that there were no antibodies
directed against catalase in the sera of SLE patients. How-
ever, we had observed antibodies against the extracellular
SOD1. It would be interesting to see if there are antibodies
against HNE-modified catalase, since HNE modification
of the enzyme could enable it to behave as a neoantigen
[23]. Recent data show that transgenic mice over-express-
ing human catalase localized to the mitochondria lived
4.5 months longer than the wild type controls [24], show-
ing the importance of catalase in aging and how HNE-
modification of this important antioxidant enzyme could
be deleterious.
To test whether the catalase promoter single nucleotide
polymorphism (SNP); rs1001179, was associated with
SLE in such a way to explain our previous linkage at
11p13, we performed a family-based association analysis.
Since we have multigenerational, multiplex families, we
have used pedigree disequilibrium test (PDT). We have
used 3 statistics, S1 (avePDT), S2 (SumPDT) and S3
(genoPDT) on all the families consisting of only sibpairs
(TD1), only triads(TD2) or both (TD2) samples to assess
the genetic association. All the test statistics were non-sig-
nificant (p > 0.05) in our data (Table 1), which suggested
that this SNP is not associated with SLE.
Previous results from our group [11,25] show sufficient
evidence to establish genetic linkage at chromosome
11p13. A recent study also detected a marker on the same
locus in families with discoid lupus erythematosus [26].
The mass spectrum showing the tryptic fragments of the 80 kD band analyzed by MALDI-TOF-MS that matched to sequences  from catalase Figure 4
The mass spectrum showing the tryptic fragments of the 80 kD band analyzed by MALDI-TOF-MS that 
matched to sequences from catalase. The Coomassie stained band migrating at 80 kD was excised and subjected to in-gel 
tryptic digestion and MALDI-TOF-MS. The mass of each individual peak was used to perform a Mascot Search, which identified 
human catalase as the primary candidate antigen (38% match). Of the 59 mass values searched, 19 of them matched to 
sequences obtained from catalase. The probability based Mowse score obtained for the Mascot search analysis was 100, where 
a score of 64 is significant (p < 0.05). X-axis gives the mass to charge ratio (m/z) and Y-axis gives the intensity of the peaks in 
counts.BMC Medical Genetics 2008, 9:62 http://www.biomedcentral.com/1471-2350/9/62
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In addition, the SNP we investigated for this study
(rs1001179), which results in a C/T substitution at posi-
tion -262 in the catalase promoter region, has been shown
to influence transcription factor binding and reporter
gene transcription [27]. Furthermore, it has also been
shown to be associated with increased blood levels of cat-
alase. Catalase activity measured from serum samples of
SLE patients have been shown to be significantly lower
than normal controls [27]. Moreover, lipid peroxidation
as measured by serum MDA concentration was signifi-
cantly elevated in SLE patients and was positively corre-
lated with the SLE activity index [28].
On further review of the hapmap around the region of
11p13 where catalase is found to be mapped, strikingly,
catalase is found to be mapped within one single hap-
loblock in the CEU, CHB and JPT populations. The only
exception is the Yoruba tribe, wherein, the catalase gene is
split into three haploblocks. This tribe most likely repre-
sents the African-Americans haploblock. On further
review of the coding SNP's in the catalase gene, we found
5 SNPs, namely rs35677492, rs17880442, rs11032709,
rs769217 and rs17886350, however, every single of these
coding SNP's was a non-informative synonymous SNP.
Using an unique 3 base SNP assay developed in house
[29], we studied one of the above SNP's (rs769217) along
with 3 others (rs1049982; found at the 5'-UTR region,
rs11546300 and rs3180560; found at the 3'UTR region)
and our results suggest a linkage in the region but no asso-
ciation of the catalase gene with SLE (results not shown).
These results confirm our previously reported linkage in
this region (11).
Catalase has also been implicated in another autoim-
mune and polygenic disease, viz. vitiligo [30]. We have
correlated thrombocytopenia with the severity of SLE with
a genetic marker located in the region of the genome that
also contains catalase. The present results, despite the
small number of patients, however, suggest that the
genetic polymorphism of catalase does not play a signifi-
cant role in the development of SLE in the African-Ameri-
can population, even though the frequency of the variant
allele in our SLE samples is 3 times what NCBI reports for
their 48 African American samples (0.126 vs. 0.042).
Nonetheless, our results strongly implicate catalase to be
one of the major protein targets of HNE-modification in
the RBC membranes of SLE patients. Previously, we and
others have shown increased oxidative damage in SLE
[11].
Conclusion
The current data suggests catalase to be one of the proteins
modified due to this oxidative stress. Even though catalase
may not be a susceptibility gene for SLE, nonetheless, cat-
alase is oxidatively modified among SLE patients. This
suggests a possible role between oxidative modification of
catalase and its affects on enzymatic activity in SLE. An
oxidatively modified catalase could be one of the reasons
for lower enzymatic activity among SLE subjects, which in
turn could favor the accumulation of deleterious hydro-
gen peroxide. Furthermore, HNE-products are potential
neoantigens and could be involved in the pathogenesis of
SLE. Decrease in catalase activity could affect the oxidant-
antioxidant balance. Chronic disturbance of this balance
in patients with SLE may work favorably for the premature
onset of atherogenesis with severe vascular effect [20].
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